



PLI SCHEME PHARMACEUTICALS

Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers



Aatmanirbhar Bharat Vision

- With a vision to make India self-reliant, the Indian Government has been actively taking steps through various policies under the flagship umbrella of Atmanirbhar Bharat scheme
- The PLI for pharmaceuticals was introduced with aim to enhance India's manufacturing capabilities by increasing investment & production along with contributing to product diversification of high value goods in the pharmaceutical sector
- One of the further objectives of the scheme is to create global champions out of India who have the potential to grow in size and scale using cutting edge technology and thereby penetrate the global value chains
- In these lines, the Union Cabinet vide a press release dated Feb 24th, 2021, announced a PLI scheme for Pharmaceutical's products, which was notified by DoP vide letter dated March 3rd, 2021
- The PLI Scheme will be implemented within the overall budget outlay of INR 15,000 Crores over a period of 6 years

Key Highlights

- The duration of scheme will be from FY 2020-21 to FY 2028-29 (Incentive Period – FY 2022-23 TO FY 2027-28)
- Base year shall be FY 2019-20 for the purpose of computation of incremental sales of manufacturing goods
- An applicant may submit a claim for disbursement of incentive on Quarterly/Half Yearly/Annual basis.





Eligible Products

Category 1

Biopharmaceuticals
Complex generic drugs
Patented drugs or drugs nearing
patent expiry
Cell based or gene therapy drugs
Orphan drugs
Special empty capsules like
HPMC, Pullulan, enteric etc.
Complex excipients
Phyto-pharmaceuticals
Other drugs as approved

Category 2

Active pharmaceutical ingredients
Key Starting Materials
Drug Intermediaries

Category 3

Repurposed drugs
Auto immune drugs, anti-cancer drugs,
anti-diabetic drugs, anti-infective drugs,
cardiovascular drugs,
psychotropic drugs and
anti-retroviral drugs
in vitro diagnostic devices
Other drugs not manufactured in India
Other drugs as approved*

* Decision will be taken by DoP to include any drug based on requirement, CDSCO approvals, TC opinion which shall take into account the current levels of production, availability, etc. The decision of DoP shall be aligned with the objectives of the scheme.





Target Groups

The applicants shall apply within the following three groups based on the respective GMR criterias



GMR :- Consolidated Global Manufacturing Revenues of the applicant and Group Company, if any, from the manufacturing of pharmaceutical goods and/or in vitro diagnostic medical devices. Revenues from any other source for instance R&D services, rental incomes, etc., shall be excluded for calculating the GMR.





Eligibility Criteria & Incentives

Criteria 1

Criteria 2

Incentives

Year	Min. Cumulative Investments (Cr.)			Min. percentage growth in sales			Proposed Incentive Rates		
	Group A	Group B	Group C	Group A	Group B	Group C	Cat 1	Cat 2	Cat 3
2021 -22	200	50	10	NA			NA	NA	NA
2022-23	400	100	20	7%			10%	10%	5%
2023-24	600	150	30	7%			10%	10%	5%
2024-25	800	200	40	7%			10%	10%	5%
2025-26	1000	250	50	7%			10%	10%	5%
2026-27	NA	NA	NA	7%			8%	8%	4%
2027-28	NA	NA	NA	7%			6%	6%	3%

Key Points for Considerations

- The selected participants in the scheme will be eligible for incentives on incremental sales of eligible products based on yearly threshold criteria of minimum cumulative investment and minimum percentage growth in sales of eligible products
- Availing incentives under the PLI scheme shall not affect the eligibility of the applicant to avail incentives provided by the respective State Governments or Union Territory, if any
- The investment made by applicant, which has been considered for PLI Scheme for Bulk Drugs or any other PLI Scheme shall not be considered again for the purpose of eligible investment under this Scheme





Say Hello



Gautam Pai
Founder & CEO

Awfficity Business Solutions Private Limited

T: +91 99097 74666

E: gautampai@awfficity.com



Pranav Shukla
Founder & MD

Awfficity Business Solutions Private Limited

T: +91 99042 19904

E: pranavshukla@awfficity.com



Aniket Talati
Strategic Advisor

Awfficity Business Solutions Private Limited

T: +91 98255 51448

E: anikettalati@awfficity.com

"This flyer is solely intended for sharing insights only and the same is prepared based on the best of information available to us. The details provided in the flyer is derived from the data and information available in the public domain, accessible to all. It may be changed by relevant government authorities as and when necessary, of which Awfficity takes no guarantee. Readers are solely responsible for checking and relying on any updated information provided by the relevant authorities by way of either guidelines, notifications, circulars, or any other official communication. Accordingly, readers are required to take due care and caution while relying on this information. The information provided hereinabove does not, and is not intended to, constitute legal advice; instead, all information, content, and materials available in this flyer are general in nature and for informative purpose only. All the information is provided in good faith, however, Awfficity makes no representation or warranty of any kind, express or implied, regarding its accuracy, adequacy, validity, reliability, availability, or completeness of any information."

